← Back to screener

AbCellera Biologics Inc. ABCL

Rank #2154 · Nasdaq · $3.7B market cap
Audited by KPMG LLPChartered Professional Accountants, no going-concern flag in the latest filing.
Score
31.6
P/E
-25.6
P/B
3.04
ROE
-11.9%
Op. Margin
-623.8%
Debt Ratio
25%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Weak

P/E -25.6x, P/B 3.04x. Ranks in the top 64% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -11.9%. Ranks in the top 86% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 25%. Ranks in the top 15% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Poor

Revenue decline of 92.2% year over year. Ranks in the top 99% of the universe.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2021$0.0B$-0.0B$-0.0B$0.0B-35.51508
2022$0.2B$0.2B$0.1B$0.0B66.92856
2023$0.4B$0.2B$0.2B$0.8B54.537
2024$0.5B$0.2B$0.2B$1.0B44.633
2025$0.0B$-0.2B$-0.1B$1.2B-623.825

← See the full screener